Atlas Trials

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Clinical trial NCT02749890 · COMPLETED

Trial details

NCT number
NCT02749890
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes Mellitus
Start date
2016-05-09
Primary completion
2018-05-01
Enrollment
321

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.